A light in the cognitive fog?

abstract：OBJECTIVE:To identify predictors of the virological response to antiretroviral therapy in patients in whom initial therapy has failed. METHODS:The Narval trial was designed to compare phenotyping, genotyping and standard of care for the choice of antiretroviral therapy in patients in whom a protease inhibitor (PI)-con...

journal_title：Antiviral therapy

authors： Vray M,Meynard JL,Dalban C,Morand-Joubert L,Clavel F,Brun-Vézinet F,Peytavin G,Costagliola D,Girard PM,Narval Trial Group.

更新日期：2003-10-01 00:00:00

abstract：BACKGROUND:Little is known about the efficacy, safety and tolerability of pegylated interferon plus ribavirin treatment in patients with chronic hepatitis Cvirus (HCV) infection and histologically proven fully established cirrhosis. We aimed here to evaluate the safety of this regimen in such patients and to identify b...

journal_title：Antiviral therapy

authors： Roffi L,Colloredo G,Pioltelli P,Bellati G,Pozzpi M,Parravicini P,Bellia V,Del Poggio P,Fornaciari G,Ceriani R,Ramella G,Corradi C,Rossini A,Bruno S,Gruppo Epatologico Lombardo.

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND/AIMS:The role of antibody in hepatitis C virus (HCV) infection remains unclear although many reports attest to its role in viral clearance. Here we describe epitopes that are recognized by antibody present in the serum of infected patients and show that such epitopes can induce neutralizing antibodies. METH...

journal_title：Antiviral therapy

authors： Grollo L,Torresi J,Drummer H,Zeng W,Williamson N,Jackson DC

更新日期：2006-01-01 00:00:00

abstract：:Chronic infection with HBV or HCV can lead to the development of hepatocellular carcinoma (HCC). The major risk factors for HBV-related HCC are persistent presence of hepatitis B e antigen (HBeAg) and/or high serum HBV DNA levels, and cirrhosis. The major risk factor for HCV-related HCC is cirrhosis. One randomized do...

journal_title：Antiviral therapy

authors： Kwon H,Lok AS

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:Serum HBV DNA level is crucial in the management of chronic hepatitis B (CHB); however, the assay is expensive and cannot be used widely. Therefore, we explored the possibility of hepatitis B surface antigen (HBsAg) quantification as a surrogate marker for HBV DNA level in CHB patients. METHODS:A total of 2...

journal_title：Antiviral therapy

authors： Su TH,Hsu CS,Chen CL,Liu CH,Huang YW,Tseng TC,Liu CJ,Chen PJ,Lai MY,Chen DS,Kao JH

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Human cytomegalovirus (HCMV) infections remain a major problem in immunocompromised patients. Three antiviral agents, ganciclovir (GCV), foscarnet (FOS) and cidofovir (CDV), are currently approved for the treatment of HCMV infections. They all target the viral DNA polymerase and are associated with significa...

journal_title：Antiviral therapy

authors： Drouot E,Piret J,Boivin G

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:The emergence of human monkeypox and the potential use of recombinant variola and monkeypox viruses as biological terrorist agents have necessitated the development of therapeutic and prophylactic therapies. The primary, or index, cases of smallpox and/or human monkeypox will likely be identified by a charac...

journal_title：Antiviral therapy

authors： Parker S,Schriewer J,Oberle C,Robertson A,Lanier R,Painter G,Buller RM

更新日期：2008-01-01 00:00:00

abstract：:This article describes the development of a novel sequential sampling method for the surveillance of transmitted HIV drug resistance by cross-sectional survey. Two commonly used sequential sampling methods are described and their applicability to the problem of classifying the prevalence of transmitted HIV drug resist...

journal_title：Antiviral therapy

authors： Myatt M,Bennett DE

更新日期：2008-01-01 00:00:00

abstract：:Clinical research has indicated that the use of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) therapy is associated with a risk of long-term toxicity syndromes, and that the aetiopathogenesis of these adverse effects is independent of the antiretroviral effects of these drugs. In re...

journal_title：Antiviral therapy

authors： Nolan D,John M,Mallal S

更新日期：2001-09-01 00:00:00

abstract：BACKGROUND:Cidofovir (CDV) is an acyclic nucleoside phosphonate that exhibits a potent antiviral activity against several DNA viruses. In previous studies, CDV has been shown to significantly reduce the clinical severity and the viral shedding in primary caprine herpesvirus type-1 (CpHV-1) infection in goats. CpHV-1 is...

journal_title：Antiviral therapy

authors： Camero M,Crescenzo G,Marinaro M,Tarsitano E,Bellacicco AL,Armenise C,Buonavoglia C,Tempesta M

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Alternatives to the available stavudine-containing paediatric fixed-dose combination (FDC) tablets are rapidly needed due to concerns regarding the cumulative toxicity of long-term stavudine exposure. We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lam...

journal_title：Antiviral therapy

authors： Chokephaibulkit K,Cressey TR,Capparelli E,Sirisanthana V,Muresan P,Hongsiriwon S,Ngampiyaskul C,Limwongse C,Wittawatmongkol O,Aurpibul L,Kabat B,Toye M,Smith ME,Eksaengsri A,McIntosh K,Yogev R,IMPAACT P1069 Team.

更新日期：2011-01-01 00:00:00

abstract：:Ribavirin is a guanosine analogue that has little antiviral activity when used alone, but considerably enhances the efficacy of conventional and pegylated interferon in the treatment of hepatitis C virus (HCV). The precise mode of action of ribavirin is not fully understood; however, it is crucial for the achievement ...

journal_title：Antiviral therapy

authors： Dusheiko G,Nelson D,Reddy KR

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Antiviral and immune-modulating properties of low-molecular-weight heparin (LMWH) against coronaviridae have been reported by in vitro studies, but no in vivo evidence is yet available. We sought to know whether the timing of prophylactic doses of LMWH during the course of COVID-19 may affect the time to SAR...

journal_title：Antiviral therapy

authors： Trunfio M,Salvador E,Gaviraghi A,Audagnotto S,Marinaro L,Motta I,Casciaro R,Ghisetti V,Fava C,Bonora S,Di Perri G,Calcagno A,e-COVID Study Group.

更新日期：2021-01-18 00:00:00

abstract：:Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly inf...

journal_title：Antiviral therapy

authors： Xie X,Jiang Y,Zeng Y,Liu H

更新日期：2020-06-04 00:00:00

abstract：BACKGROUND:Tenofovir disoproxil fumarate (TDF)-based regimen is a treatment option for HIV-infected patients. TDF dose adjustment is recommended in patients with impaired renal function. We assessed the impact of TDF dose adjustment on renal function and tenofovir trough concentration. METHODS:Fourteen HIV patients fo...

journal_title：Antiviral therapy

authors： Bregigeon S,Solas C,Faucher O,Obry-Roguet V,Tamalet C,Poizot-Martin I

更新日期：2017-01-01 00:00:00

abstract：:Zalcitabine (ddC) is a nucleoside analogue reverse transcriptase inhibitor with demonstrated clinical benefit in combination use. More widespread use of zalcitabine has been limited by a number of factors including peripheral neuropathy and three times daily dosing. However, screening for the risk factors for peripher...

journal_title：Antiviral therapy

authors： Moyle GJ,Gazzard BG

更新日期：1998-01-01 00:00:00

abstract：BACKGROUND:Hepatitis C virus genotype 1B responds poorly to treatment with interferon, in contrast to the more interferon-sensitive genotypes 2 and 3. Studies on combination therapy regimens with PEG-interferon and ribavirin report sustained response rates that generally do not exceed 50%, in contrast to sustained resp...

journal_title：Antiviral therapy

authors： Schinkel J,Spaan WJ,Kroes AC

更新日期：2004-04-01 00:00:00

abstract：:HIV-HBV-coinfected patients require optimal control of viral replication in order to prevent the development of severe comorbidities, such as liver cirrhosis and hepatocellular carcinoma. The genetic diversity of HBV is a poorly investigated factor of such viral replication in HIV-infected hosts. HBV genome diversity ...

journal_title：Antiviral therapy

authors： Lacombe K,Boyd A,Gozlan J,Lavocat F,Girard PM,Zoulim F

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:In China, the clinical management of chronic hepatitis B (CHB) is complicated by the use of variousnucleoside/nucleotide analogue (NUC) regimens in treatment-naive patients, including NUCs with low genetic barriers to resistance, with/without add-on therapy and de novo NUC combinations. This longitudinal obs...

journal_title：Antiviral therapy

authors： Jia J,Tang H,Ning Q,Jiang J,Dou X,Zhang M,Zhang S,Shang J,Lu W,Ye Y,Wang X,Li M,Liu J,Bo Q,Tan W,EVOLVE Study Group.

更新日期：2018-01-01 00:00:00

abstract：:The balance of virus production and clearance for untreated patients with chronic hepatitis C virus (HCV) results in a decline of viraemia when initiating active antiviral treatment. During the first phase of interferon-alpha therapy, after a delay of about 8-9 h, the kinetics of the viral load is characterized by a r...

journal_title：Antiviral therapy

authors： Herrmann E,Neumann AU,Schmidt JM,Zeuzem S

更新日期：2000-06-01 00:00:00

abstract：:Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past...

journal_title：Antiviral therapy

authors： Calle Serrano B,Manns MP

更新日期：2012-01-01 00:00:00

abstract：:Although zidovudine (ZDV) is effective in HIV-1-infected patients, the duration of its efficacy may be short when treatment is started in advanced HIV disease. This pilot prospective case-control study was designed to evaluate the combination of ZDV plus didanosine [ddI] compared with ZDV monotherapy as an initial the...

journal_title：Antiviral therapy

authors： Gatell JM,Leal M,Mallolas J,Vidal C,Pumarola T,Parra R,Padró S,Caruz A,Falgueras T,Rey C,Sánchez-Quijano A,Torres Y,Lissen E,Jiménez de Anta MT,Soriano E

更新日期：1996-04-01 00:00:00

abstract：BACKGROUND:Neuraminidase (NA) inhibitors (NAIs), including oseltamivir and zanamivir, play an important therapeutic role against influenza infections in immunocompromised patients. In such settings, however, NAI therapy may lead to the emergence of resistance involving mutations within the influenza surface genes. The ...

journal_title：Antiviral therapy

authors： Abed Y,Schibler M,Checkmahomed L,Carbonneau J,Venable MC,Fage C,Giannotti F,Goncalves AR,Kaiser L,Boivin G

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:New drugs are needed to combat HBV infection. We investigated the anti-HBV activity of the deoxycytidine analogue FNC, which has anticancer activity and has been found to inhibit HCV replication. METHODS:In this study, a human hepatoma HepG2.2.15 cell culture system and duck HBV (DHBV) infection model were ...

journal_title：Antiviral therapy

authors： Zheng L,Wang Q,Yang X,Guo X,Chen L,Tao L,Dong L,Li Y,An H,Yu X,Wang Q,Chang J

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:Suboptimal doses of ribavirin have been suggested to explain the diminished efficacy of pegylated interferon (PEG-IFN) plus ribavirin in hepatitis C virus (HCV)-HIV-coinfected patients. METHODS:A cohort of 104 coinfected patients and an age-, sex- and genotype-matched cohort of HCV-monoinfected patients (n ...

journal_title：Antiviral therapy

authors： Tural C,Galeras JA,Planas R,Coll S,Sirera G,Giménez D,Salas A,Rey-Joly C,Cirera I,Márquez C,Tor J,Videla S,García-Retortillo M,Clotet B,Solà R

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Damage to mitochondria (mt) is a major side effect of highly active antiretroviral therapy (HAART) that includes a nucleoside reverse transcriptase inhibitor (NRTI). Such damage is associated with the onset of lipodystrophy in HAART-treated HIV+ patients. To further investigate mt changes during this syndrom...

journal_title：Antiviral therapy

authors： Galluzzi L,Pinti M,Guaraldi G,Mussini C,Troiano L,Roat E,Giovenzana C,Nemes E,Nasi M,Orlando G,Salomoni P,Cossarizza A

更新日期：2005-01-01 00:00:00

abstract：:Infection with influenza viruses, including seasonal, avian and pandemic viruses, remains a worldwide public health problem. Although influenza virus infection is both vaccine preventable and drug treatable, high rates of mutation and reassortment of viruses can result in reduced effectiveness of vaccines or drugs. Cu...

journal_title：Antiviral therapy

authors： Nguyen HT,Fry AM,Gubareva LV

更新日期：2012-01-01 00:00:00

abstract：:A novel severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) has been identified as the aetiological agent of SARS. We previously isolated and characterized SARS-CoV and SARS-CoV-like viruses from human and animals, respectively, suggesting that SARS could be transmitted from wild/farmed animals ...

journal_title：Antiviral therapy

authors： Zheng BJ,Guan Y,Hez ML,Sun H,Du L,Zheng Y,Wong KL,Chen H,Chen Y,Lu L,Tanner JA,Watt RM,Niccolai N,Bernini A,Spiga O,Woo PC,Kung HF,Yuen KY,Huang JD

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND:Increasing efavirenz (EFV) dose from 600 mg to 800 mg daily has been suggested with concomitant rifampicin (RFN), as induction of cytochrome P450 isoenzymes may reduce EFV plasma concentrations. METHODS:Individuals from the CIPRA-South Africa cohort taking EFV-based antiretroviral therapy with concomitant t...

journal_title：Antiviral therapy

authors： Orrell C,Cohen K,Conradie F,Zeinecker J,Ive P,Sanne I,Wood R

更新日期：2011-01-01 00:00:00

abstract：OBJECTIVE:A high level of adherence to antiretroviral therapy is required for complete suppression of HIV replication, immunological and clinical effectiveness. We investigated whether cognitive behaviour therapy can improve medication adherence. DESIGN:Prospective randomized 1-year trial. SETTING:Collaboration of HI...

journal_title：Antiviral therapy

authors： Weber R,Christen L,Christen S,Tschopp S,Znoj H,Schneider C,Schmitt J,Opravil M,Günthard HF,Ledergerber B,Swiss HIV Cohort Study.

更新日期：2004-02-01 00:00:00